Mavacamten治疗转诊室间隔减容术的梗阻性肥厚型心肌病:VALOR-HCM第128周结果
VALOR-HCM试验第128周结果显示,在因严重症状被转诊行室间隔减容术的梗阻性肥厚型心肌病患者中,仅15.7%达到室间隔减容术或仍符合指南指征的复合终点,80.5%患者NYHA心功能至少改善1级,88%患者转为商业Mavacamten继续治疗。
要点
- 第128周仅15.7%患者行室间隔减容术或仍符合指南指征。
- 80.5%患者NYHA心功能至少改善1级,48.1%改善至少2级。
- 静息和Valsalva左室流出道压差分别持续降低38.2 mmHg和59.4 mmHg。
核心结论
- 在严重症状性梗阻性肥厚型心肌病患者中,第128周观察到持续免于室间隔减容术,近90%患者长期继续使用Mavacamten。
研究设计与样本
- 双盲随机安慰剂对照多中心试验,美国19个中心,纳入因室间隔减容术转诊的症状性梗阻性肥厚型心肌病患者,2020年7月至2021年10月入组。
- 初始随机至Mavacamten组继续用药128周,安慰剂至Mavacamten组从第16周至第128周(暴露112周),根据超声心动图左室流出道压差和左室射血分数进行剂量滴定。
主要发现
- 第128周,总样本108例中17例(15.7%)达到复合终点(7例行室间隔减容术,1例符合室间隔减容术指征,9例室间隔减容术状态不可评估)。
- 108例中87例(80.5%)NYHA心功能至少改善1级,52例(48.1%)至少改善2级。
- 静息和Valsalva左室流出道压差分别持续降低38.2 mmHg和59.4 mmHg。
- 108例中15例(13.8%;5.41/100患者年)出现左室射血分数<50%(2例左室射血分数≤30%;1例死亡),其中12例(80%)继续治疗;新发房颤11例(10.2%;4.55/100患者年)。
临床怎么用
- 对于严重症状性梗阻性肥厚型心肌病且被转诊行室间隔减容术的患者,长期Mavacamten治疗可持续降低室间隔减容术需求并改善心功能。
- 治疗期间需根据超声心动图左室流出道压差和左室射血分数进行剂量滴定,并监测左室射血分数下降和新发房颤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128. METHODS: A double-blind randomized placebo-controlled multicenter trial at 19 sites in the United States included symptomatic obstructive HCM patients referred for SRT (enrollment July 2020 through October 2021). The group initially randomized to mavacamten continued the drug for 128 weeks and the placebo to mavacamten group from week 16 to 128 (112-week exposure). Dose titrations were performed using echocardiographic left ventricular outflow tract gradient and left ventricular ejection fraction measurements. The principal end point was proportion of patients proceeding with SRT or remaining guideline-eligible at week 128. RESULTS: At week 128, 17 of 108 (15.7%) patients in the total study sample met the composite end point (7 underwent SRT, 1 was SRT-eligible, and 9 SRT-status unevaluable). Additionally, 87 of 108 (80.5%) patients demonstrated ≥1 New York Heart Association class improvement by week 128, and 52 of 108 (48.1%) demonstrated ≥2, with a sustained reduction in resting and Valsalva left ventricular outflow tract gradients of 38.2 mm Hg and 59.4 mm Hg, respectively. Ninety-five of 108 (88%) patients transitioned to commercial mavacamten. Overall, 15 of 108 (13.8%) patients (5.41 per 100 patient-years) had an left ventricular ejection fraction <50% (2 with left ventricular ejection fraction ≤30%; 1 death). Of these, 12 of 15 (80%) continued treatment. New-onset atrial fibrillation occurred in 11 (10.2%) patients (4.55 per 100 patient-years). CONCLUSIONS: In severely symptomatic obstructive HCM patients, sustained freedom from SRT was observed at 128 weeks, with nearly 90% patients remaining on long-term mavacamten. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04349072.
引用
- Desai MY, Wolski K, Owens A, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. Circulation. 2024. PMID: 39556124. doi:10.1161/CIRCULATIONAHA.124.072445
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。